Chlamydia Infections - Epidemiology Forecast - 2032

DelveInsight’s "Chlamydia – Epidemiology Forecast–2032" report delivers an in-depth understanding of the historical and forecasted epidemiology of Chlamydia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chlamydia: Disease Understanding
Chlamydia Overview
Chlamydial infection, caused by Chlamydia trachomatis, is the most common bacterial sexually transmitted infection (STI). Age is a strong predictor of risk for chlamydial infections, with the highest infection rates in women occurring during ages 15–24 years. As most individuals with the infection are asymptomatic, it is often left untreated, increasing the risk of transmission and serious health consequences in both sexes. If symptoms occur, they usually appear two to six weeks after infection. Symptoms can include vaginal pain and bleeding, painful urination, and an abnormal discharge from the vagina, urethra, or rectum.
Untreated infection can result in serious complications such as pelvic inflammatory disease, infertility, ectopic pregnancy in women, and epididymitis and orchitis in men. Maternal infection is associated with serious adverse outcomes in neonates, such as preterm birth, low birth weight, conjunctivitis, nasopharyngeal infection, and pneumonia. Screening for chlamydia is implemented in several countries and regions, including the US and the UK, to reduce the risks. Screening is recommended in all women younger than 25 years, in all pregnant women, and in women who are at increased risk of infection.
The Aptima Combo 2 Assay and the Xpert CT/NG were the first tests cleared for extragenital diagnostic testing to detect the presence of the bacteria Chlamydia trachomatis via the throat and rectum. These tests were previously only cleared for testing urine, vaginal and endocervical samples. The availability of these two tests helped fill an unmet public health need by allowing for more screening. Recently, US FDA approved using the Binx Health IO CT/NG Assay at point-of-care settings to help with more quick and appropriate treatment of chlamydia. Access to faster diagnostic results and appropriate treatments will make significant strides in combatting Chlamydia infections.
Treating C. trachomatis prevents adverse reproductive health complications and continued sexual transmission. Furthermore, treating the sex partners prevent reinfection and infection of other partners. Also, treating pregnant women usually prevents C. trachomatis in neonates during birth. For the treatment of chlamydia infection, the Centers for Disease Control and Prevention (CDC) recommends 100 mg of doxycycline twice daily for 7 days. Alternate regimens include oral administration of either 1 g of azithromycin in a single dose of Levofloxacin 500 mg orally once daily for 7 days.
While antibiotics have successfully treated most uncomplicated C. trachomatis urogenital infections, treatment does not generally resolve persistent infections or prevent autoimmunity. Repeat and persistent infections are common among at-risk adolescent and young adult populations. Even with appropriate detection, there is increasing evidence for antibiotic resistance to the common drugs used to treat C. trachomatis.
Chlamydia: Epidemiology
The Chlamydia epidemiology division provides insights about the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical and forecasted Chlamydia epidemiology segmented as the diagnosed incident cases of chlamydia, gender-specific cases of chlamydia, symptom-specific cases of chlamydia, and age-specific cases of chlamydia. The report includes the Diagnosed incident scenario chlamydia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country-wise Chlamydia Epidemiology
The epidemiology segment also provides the Chlamydia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed incident population of chlamydia in the 7MM countries was 3,453,387 cases in 2021.
As per the estimates, the United States had the highest diagnosed incident Chlamydia population in 2021. Among the EU5 countries, Germany had the highest diagnosed incident population of chlamydia with 446,881 cases, followed by France in 2021. On the other hand, Italy had the lowest diagnosed incident population of 1,301 cases in 2021.
Scope of the Report
• Chlamydia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Chlamydia Epidemiology Report and Model provide an overview of the risk factors and global trends of chlamydia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of chlamydia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of chlamydia.
• The report provides the segmentation of the Chlamydia epidemiology by diagnosed incident cases of chlamydia in the 7MM.
• The report provides the segmentation of the Chlamydia epidemiology by gender-specific cases of chlamydia in the 7MM.
• The report provides the segmentation of the Chlamydia epidemiology by age-specific cases of chlamydia in the 7MM.
• The report provides the segmentation of the Chlamydia epidemiology by symptom-specific cases of chlamydia in the 7MM.

Report Highlights
• 11-year Forecast of Chlamydia epidemiology
• 7MM Coverage
• Diagnosed Incident Cases of Chlamydia
• Gender-specific Cases of Chlamydia
• Age-specific Cases of Chlamydia
• Symptom-specific Cases of Chlamydia

KOL Views
We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What are the major factors that will drive the change in the patient population with Chlamydia during the forecast period (2019–2032)?
• What are the key findings pertaining to the Chlamydia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
• What would be the total number of patients with chlamydia across the 7MM during the forecast period (2019–2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?
• What are the disease risk, burdens, and unmet needs of chlamydia?
• What are the currently available treatments for chlamydia?
Reasons to buy
Chlamydia Epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global Chlamydia market
• Quantify patient populations in the global Chlamydia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chlamydia therapeutics in each of the markets covered
• Understand the magnitude of the Chlamydia population by its Diagnosed incident cases.
• Understand the magnitude of the Chlamydia population by its gender-specific cases.
• Understand the magnitude of the Chlamydia population by its age-specific cases.
• Understand the magnitude of the Chlamydia population by its symptom-specific cases.
• The Chlamydia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Chlamydia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032
According to the Centers for Disease Control and Prevention (CDC, 2021), a sexually transmitted disease surveillance report, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported to the CDC, making it the most common notifiable condition in the United States in the year 2019. This case count corresponded to an increase of 2.8% compared with the rate in 2018. Rates of reported cases among men are generally lower than rates among women. Moreover, these rates were highest among adolescents and young adults. In 2019, almost two-thirds (61.0%) of all reported chlamydia cases were among persons aged 15–24 years. Among females aged 15–24 years, the population targeted for chlamydia screening, the overall rate of reported cases of chlamydia was 3,728.1 cases per 100,000 females, an increase of 10.0% from 2015.
According to the 2018 Annual epidemiological report by the European Centre for Disease Prevention and Control (2020), the crude notification rate for the 23 EU/EEA countries with comprehensive surveillance systems was 146 per 100,000 population with 406,406 confirmed cases of chlamydia infection. The United Kingdom accounted for 60% of all reported cases in 2018, while the combined case numbers of Denmark, Norway, Sweden, and the United Kingdom amount to 82% of all cases reported in the EU/EEA in 2018. Data on gender was reported for 404,402 cases (99.5% of all confirmed cases). The overall male-to-female ratio in 2018 was 0.8, with 176,096 cases reported in men, compared with 228 306 cases among women. Among countries with comprehensive surveillance systems, the overall notification rate was 128 per 100,000 in men and 161 per 100,000 in women.